Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nutra PharmaNPHC 3-Year ROIIC % is 25.49 as of Dec. 2025, which is 27% above its 10-year median of 20.03. The stock has 5 warning signs investors should review. Among 946 Drug Manufacturers companies, Nutra Pharma ranks better than 74.74% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Nutra Pharma's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 25.49%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Nutra Pharma's 3-Year ROIIC % or its related term are showing as below:
NPHC's 3-Year ROIIC % is ranked better than 74.74% of 946
companies
in the Drug Manufacturers industry
Industry Median: 3.61
vs NPHC: 25.49
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Nutra Pharma 3-Year ROIIC % Related Terms
Nutra Pharma 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Nutra Pharma's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NPHC vs UPC, CBIH, SXTC: 3-Year ROIIC % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Nutra Pharma's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nutra Pharma 3-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Nutra Pharma's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Nutra Pharma's 3-Year ROIIC % falls into.
Nutra Pharma's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -1.462 (Dec. 2025) - -1.836 (Dec. 2022) )
/
( 10.708 (Dec. 2025) - 9.241 (Dec. 2022) )
=
0.374
/
1.467
=
25.49%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Nutra Pharma (NPHC) has a 3-Year ROIIC % of 25.49 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Nutra Pharma and its competitors. This is 27% above median its historical median of 20.03. According to the industry distribution chart, Nutra Pharma ranks #239 out of 946 companies in the Drug Manufacturers industry, placing it in the top 25.3%.
Is Nutra Pharma's 3-Year ROIIC % too high?
Nutra Pharma's current 3-Year ROIIC % of 25.49 is 27% above median its 10-year median of 20.03. The Drug Manufacturers industry median 3-Year ROIIC % is 3.61. Nutra Pharma's value of 25.49 is 606.1% above this industry median. Based on the distribution chart, Nutra Pharma ranks #239 out of 946 companies in the Drug Manufacturers industry, which is above the industry midpoint.
How does Nutra Pharma's 3-Year ROIIC % compare to UPC and CBIH?
According to the Drug Manufacturers industry distribution chart, Nutra Pharma ranks #239 out of 946 companies for 3-Year ROIIC %. This puts Nutra Pharma in the upper half of its industry. The industry median 3-Year ROIIC % is 3.61. Nutra Pharma's value of 25.49 is 606.1% above this benchmark. While the company's 10-year median is 20.03 vs. the industry median of 3.61, Nutra Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Drug Manufacturers company?
The median 3-Year ROIIC % among Drug Manufacturers companies is 3.61, based on 946 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nutra Pharma's current 3-Year ROIIC % of 25.49 is 606.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Nutra Pharma and its competitors. For the Drug Manufacturers industry, the median 3-Year ROIIC % is 3.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nutra Pharma's current 3-Year ROIIC % is 25.49, which is 27% above median its own 10-year median of 20.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nutra Pharma stock overvalued right now?
Nutra Pharma (NPHC) has a current 3-Year ROIIC % of 25.49. The current 3-Year ROIIC % is 25.49, which is 27% above median its 10-year median of 20.03 and 606.1% above the Drug Manufacturers industry median of 3.61. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Nutra Pharma (NPHC), the current 3-Year ROIIC % is 25.49 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Nutra Pharma Corp operates as a biopharmaceutical company with intellectual property for drugs that treat autoimmune disorders, viral diseases, and pain. It is focused on homeopathic and drug discovery research and clinical development, and has developed four homeopathic drugs for the relief of pain: Nyloxin and Nyloxin Extra Strength, Pet Pain-Away, Equine Pain-Away, and Luxury Feet. Additionally, the company has developed two drug candidates: RPI-78M, to treat neurological diseases and autoimmune diseases; and RPI-MN, to treat viral diseases, including HIV/AIDS and Herpes. Nutra Pharma produces, markets, and distributes its branded products both domestically and internationally.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NPHC has been successfully added to your 
